金赛欣®

Search documents
长春高新(000661) - 2025年8月31日投资者关系活动记录表
2025-09-01 05:12
Group 1: Company Overview and Strategy - The company has actively engaged in strategic adjustments and enhanced innovation investments, focusing on drug research and development with multiple core technology platforms that possess independent intellectual property rights and international competitiveness [2][4]. - The company aims to strengthen its product layout in high-demand therapeutic areas, particularly in endocrine metabolism and women's health, to support sustainable development and international strategic goals [2][3]. Group 2: Key Products and Market Potential - The subsidiary, Jinsai Pharmaceutical, has launched Fuxin Qibai monoclonal antibody (Jinbeixin®), the first approved anti-IL-1β monoclonal antibody in China, filling a gap in long-acting targeted therapy for gout [3][4]. - Fuxin Qibai is expected to expand its indications to include chronic anti-inflammatory treatment and various other conditions, enhancing its market potential [3][4]. Group 3: Women's Health Product Line - Jinsai Pharmaceutical has developed long-acting FSH preparations, which are anticipated to improve patient compliance, and has launched Jinxi Xin®, the first water-soluble progesterone preparation in China [5][6]. - The company plans to deepen its focus on women's health by providing comprehensive health management throughout the female lifecycle and developing a competitive product pipeline [5][6]. Group 4: Oncology Product Development - The company’s oncology product, Meishiya®, addresses cancer cachexia, which affects 20%-30% of cancer patients and significantly impacts treatment outcomes and quality of life [6][7]. - Meishiya® is also being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV), with clinical trials expected to complete by Q1 2026 [6][7]. Group 5: Long-term Growth and Innovation - The company’s long-acting growth hormone is the only product approved for three major indications, supported by five years of real-world data confirming its long-term safety [7][8]. - The company is focusing on diversifying its revenue streams by expanding into overseas licensing of innovative drugs and developing a robust pipeline in major diseases [8][9]. Group 6: Research and Development Platforms - The company has established multiple core technology platforms that integrate artificial intelligence to enhance drug design, screening, evaluation, and formulation processes [18][19]. - The platforms aim to address industry pain points, such as low targeting efficiency and safety risks associated with traditional drug delivery methods [18][19]. Group 7: Pipeline and Clinical Trials - The company is advancing several innovative drug candidates across various therapeutic areas, including endocrine metabolism, oncology, and women's health, with a focus on first-in-class or best-in-class products [9][10]. - Key projects include GenSci098 for thyroid eye disease and GenSci074 for vasomotor symptoms, both showing promising clinical results [10][11].